The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 04, 2014
Filed:
Oct. 26, 2012
Roman Manetsch, Tampa, FL (US);
Richard Matthew Cross, Brandon, FL (US);
Niranjan Kumar Namelikonda, Tampa, FL (US);
Dennis Edward Kyle, Lithia, FL (US);
Tina Susanna Mutka, Tampa, FL (US);
Alexis Nichole Lacrue, Temple Terrace, FL (US);
Jordany Richarlson Maignan, Tampa, FL (US);
Fabian Ernesto Saenz, Quito, EC;
Roman Manetsch, Tampa, FL (US);
Richard Matthew Cross, Brandon, FL (US);
Niranjan Kumar Namelikonda, Tampa, FL (US);
Dennis Edward Kyle, Lithia, FL (US);
Tina Susanna Mutka, Tampa, FL (US);
Alexis Nichole LaCrue, Temple Terrace, FL (US);
Jordany Richarlson Maignan, Tampa, FL (US);
Fabian Ernesto Saenz, Quito, EC;
University of South Florida, Tampa, FL (US);
Abstract
Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of ainfection in the recipient subject, or to reduce the likelihood of the onset or establishment of ainfection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.